# BPC-157 TB-500: The Wolverine Blend, Read Honestly From the Research > BPC-157 TB-500 is the 'Wolverine' research pairing of two tissue-repair peptides. A friendly digest of what each peptide's studies show, what the combination doesn't, and where the human data stop. One is a 15-amino-acid repair peptide; the other is a 7-amino-acid actin-binding fragment. We read each against its own studies, mark where the human data stop, and never pretend the combination has been tested when it hasn't. ## Two peptides, one community nickname BPC-157 TB-500 is the research-community pairing better known by its gym-forum nickname, the "Wolverine" blend. It is not one molecule. It is two distinct synthetic peptides put in the same conversation — and often the same vial — because each one touches a different part of how tissue repairs. BPC-157 is a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419 Da) derived from a protein found in human gastric juice. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889 Da) of Thymosin Beta-4, the body's principal actin-sequestering protein [3][4]. This site is a digest, not a dispensary. We summarize the peer-reviewed literature on each peptide, pair every number with the study it came from, and stay honest about one thing in particular: the blend itself — the two given together — has never been tested in a controlled study [8]. Everything below describes the components individually, in the species and models where they were actually studied. ## The BPC-157 TB-500 stack: the Wolverine pairing, combined The "Wolverine stack" idea is simple to state and harder to defend: combine BPC-157 and TB-500 and you get two repair signals at once. BPC-157 supplies a local cytoprotective and pro-angiogenic signal, up-regulating VEGFR2 with downstream Akt-eNOS activation [2]. TB-500's LKKTETQ motif binds monomeric G-actin one-to-one and regulates the cytoskeletal dynamics that drive cell migration [3]. The two are described as acting through complementary but largely non-overlapping pathways, which is the entire rationale for pairing them. That rationale is a theoretical extrapolation, not a finding. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two peptides given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 36 studies and never once mentions TB-500 or any combination [8]. If you came looking for proof the stack works, the honest answer is that the evidence is single-compound and mostly preclinical — and the [BPC-157 TB-500 side effects and the tumor-signal concern](/side-effects) deserve as much attention as the upside. ## What is the Wolverine peptide blend? Search interest in the "wolverine peptide" runs high, but much of that volume is tangled up with the comic-book character. Stripped of the name, the wolverine peptide blend is just BPC-157 plus TB-500: two synthetic peptides marketed and discussed together as a regenerative pairing. There is no standardized composition. Commercial research vials are commonly labeled with a combined per-vial mass — for example 10 mg BPC-157 with 10 mg TB-500 — but no ratio has been clinically validated [9]. The two components occupy complementary nodes of a tissue-repair network in preclinical work. BPC-157 has been studied for cytoprotection, angiogenesis, and tendon and ligament repair in rodent models [1][2]; TB-500 and its parent protein Thymosin Beta-4 have been studied for cell migration, re-epithelialization, and wound healing in animal and biochemical models [3][4]. The blend as a single product, though, has not been tested in any controlled study. ## How we read the evidence here Three rules keep this notebook honest. First, every quantitative claim — a dose, a half-life, a count — is tied to a study you can look up in [the full reference list](/references). Second, when something has only been shown in rats or in a test tube, we say so plainly rather than letting it read like a human result. Third, the gaps get the same ink as the findings: no controlled blend trial, no validated human pharmacokinetics, and a standing tumor-signal concern around Thymosin Beta-4 [5]. If you want the mechanism detail and the study-by-study record, start with [BPC-157 and TB-500 mechanisms](/research); from there it is easy to see [why researchers pair the two peptides](/research) and to weigh the [BPC-157 vs. TB-500 differences](/research) side by side. For the numbers, the [BPC-157 TB-500 dosage in animal studies](/dosage) is reported per body weight and per route. If your question is about safety, the [long-term safety and tolerability](/side-effects) page leads with the careful parts first. And if you are trying to understand whether any of this is legally available — including the [WADA prohibition status](/legal-status) and the FDA picture — the [Wolverine legal status and FDA 503A category](/legal-status) page lays out the present-tense regulatory picture. --- A pastel night-sketchbook of the BPC-157 and TB-500 record — each peptide doodled gently against its own studies, the untested combination left as a blank page, and the FDA 503A status drawn in before anything else; no clinic behind the notebook and nothing here dispensed or sold.